CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease
(2024) In Alzheimer's and Dementia 20(9). p.5819-5832- Abstract
INTRODUCTION: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). METHODS: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. RESULTS: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite)... (More)
INTRODUCTION: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). METHODS: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. RESULTS: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ−) individuals. DISCUSSION: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2024-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, chitinase 3-like protein 1, cognition, cognitively unimpaired, glial biomarkers, glial fibrillary acidic protein, preclinical, soluble triggering receptor expressed on myeloid cell 2
- in
- Alzheimer's and Dementia
- volume
- 20
- issue
- 9
- pages
- 14 pages
- publisher
- Wiley
- external identifiers
-
- scopus:85199007747
- pmid:39032119
- ISSN
- 1552-5260
- DOI
- 10.1002/alz.13862
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
- id
- d6bb6998-1710-489a-b1d8-1c59d2d76333
- date added to LUP
- 2024-11-27 10:50:13
- date last changed
- 2025-07-10 05:33:24
@article{d6bb6998-1710-489a-b1d8-1c59d2d76333, abstract = {{<p>INTRODUCTION: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). METHODS: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. RESULTS: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ−) individuals. DISCUSSION: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention.</p>}}, author = {{Warmenhoven, Noëlle and Sánchez-Benavides, Gonzalo and González-Escalante, Armand and Milà-Alomà, Marta and Shekari, Mahnaz and López-Martos, David and Ortiz-Romero, Paula and Kollmorgen, Gwendlyn and Quijano-Rubio, Clara and Minguillón, Carolina and Gispert, Juan Domingo and Vilor-Tejedor, Natalia and Arenaza-Urquijo, Eider and Palpatzis, Eleni and Ashton, Nicholas J. and Zetterberg, Henrik and Blennow, Kaj and Suárez-Calvet, Marc and Grau-Rivera, Oriol}}, issn = {{1552-5260}}, keywords = {{Alzheimer's disease; chitinase 3-like protein 1; cognition; cognitively unimpaired; glial biomarkers; glial fibrillary acidic protein; preclinical; soluble triggering receptor expressed on myeloid cell 2}}, language = {{eng}}, number = {{9}}, pages = {{5819--5832}}, publisher = {{Wiley}}, series = {{Alzheimer's and Dementia}}, title = {{CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease}}, url = {{http://dx.doi.org/10.1002/alz.13862}}, doi = {{10.1002/alz.13862}}, volume = {{20}}, year = {{2024}}, }